SABCS Poster Presentation

San Antonio Breast Cancer Symposium 2022

Download our SABCS 2022 Poster

To request a copy of our SABCS poster, please complete the form.
SABCS 600x200

Imagion Biosystems presented interim data from our Phase I study for our MagSense® HER2 breast cancer imaging agent at the leading, international 2022 San Antonio Breast Cancer Symposium on December 7th. 

Noninvasive Detection of Lymph Node Involvement in Subjects with Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Cancer 

A First-In-Human Phase 1 Study Using the MagSense® HER2 Imaging Agent

In the presentation, we report interim results of the exploratory endpoints related to detection efficacy.

The results indicate that Magnetic Resonance Imaging (MRI) detection of the MagSense imaging agent could help discriminate between suspicious, potentially cancerous nodes from normal nodes, thus tracking nodal metastisis.

In addition, when combined with standard morphological assessments, the imaging agent “has the potential to improve radiological evaluation thereby improving the standard of care clinical assessments.”

Several important findings have emerged from the interim results to date:

  • Changes in MR contrast created by the specific binding of MagSense imaging agent to tumor cells aid in resolving nodal status
  • No safety, toxicity or adverse events reported related to the imaging agent

This study was our first proof-of-principle in the clinical setting that our targeted nanoparticle technology has the potential to improve on conventional medical imaging methods.

The work was presented by Yalia Jayalakshmi, Ph.D, Chief Development Officer at Imagion Biosystems and co-authored by study principal investigators.

A full version of the poster abstract is added below. 

Request a copy of the poster and further data findings by completing the form.

Poster Abstract

Introduction Iron oxide nanoparticles have been used in preclinical and clinical research as imaging agents for decades because of their magnetic properties and their known safety profile. We have been developing the MagSense® HER2 Test Reagent (MSH2TR), a formulation of anti-human epidermal growth factor receptor 2 (HER2) conjugated iron oxide nanoparticles, for the noninvasive detection of metastatic lymph nodes to aid in staging of HER2 positive (HER2+) breast cancer patients.

Currently, nodal staging requires a patient’s lymph nodes to be surgically removed or biopsied for histopathological examination. MSH2TR is currently being investigated in a first-in-human phase I study in subjects with HER2+ primary breast cancer who, in the judgment of the investigator, have a likelihood of lymph node metastasis. Methods This phase I study is designed to be a preliminary proof-of-principle study with the primary objective of achieving an initial assessment of the safety and tolerability of the MSH2TR injectable imaging agent.

A secondary objective of the study is the confirmation that the route of administration is effective in allowing the imaging agent to reach the patient’s lymph nodes. The exploratory objectives of the study include a comparison of the two imaging modalities: magnetic resonance imaging (MRI) and a novel proprietary technology called magnetic relaxometry (MRX), to standard clinical tissue histopathology. The exploratory objectives are expected to provide a preliminary assessment as to whether the MagSense® HER2 imaging agent, when used with one or both imaging modalities, might be able to provide a non-invasive alternative to nodal biopsy. All eligible subjects receive a 30mg injection of MSH2TR into the subareolar interstitial tissue or area near and around the primary tumor. MRI of the axilla are performed before and 24 to 72 hours after MSH2TR injection followed by core biopsy or dissection of the suspected lymph node tissue as per standard of care (SOC) procedures for histopathology assessments and also for ex vivo MRX measurements using the MagSense® Relaxometry Instrument. Review of the MRI scans and histopathology are performed in respective central laboratories.

The study is currently enrolling in 4 clinical sites in Australia. Results From an interim evaluation of the first five patients that have completed the study, MSH2TR appears to be safe and well tolerated and no safety issues reported related to the imaging agent. The imaging agent, as administered, is reaching the lymph nodes. The study intends to enroll approximately 15 patients for the preliminary efficacy assessment. Safety and efficacy results from available patients’ data will be presented. Conclusion Available data to date from the ongoing phase I study show that the MagSense® HER2 imaging agent, as administered, appear to be safe and drains to the axillary lymph nodes within the timeframe of interest. Further data collection is ongoing for the preliminary evaluation of efficacy.

Questions about our poster presentation or our technology? Connect with one of our team members: